This study from UK shows even more evidence that daily bike-riding is a kind of "Miracle Pill."

263,000 bicycle commuters, average age of 53, were followed: over study period, their risk of dying from heart disease was 52% lower; risk of cancer 40% lower.

https://www.bmj.com/content/357/bmj.j1456

Association between active commuting and incident cardiovascular disease, cancer, and mortality: prospective cohort study

Objective  To investigate the association between active commuting and incident cardiovascular disease (CVD), cancer, and all cause mortality. Design  Prospective population based study. Setting  UK Biobank. Participants  263 450 participants (106 674 (52%) women; mean age 52.6), recruited from 22 sites across the UK. The exposure variable was the mode of transport used (walking, cycling, mixed mode v non-active (car or public transport)) to commute to and from work on a typical day. Main outcome measures  Incident (fatal and non-fatal) CVD and cancer, and deaths from CVD, cancer, or any causes. Results  2430 participants died (496 were related to CVD and 1126 to cancer) over a median of 5.0 years (interquartile range 4.3-5.5) follow-up. There were 3748 cancer and 1110 CVD events. In maximally adjusted models, commuting by cycle and by mixed mode including cycling were associated with lower risk of all cause mortality (cycling hazard ratio 0.59, 95% confidence interval 0.42 to 0.83, P=0.002; mixed mode cycling 0.76, 0.58 to 1.00, P<0.05), cancer incidence (cycling 0.55, 0.44 to 0.69, P<0.001; mixed mode cycling 0.64, 0.45 to 0.91, P=0.01), and cancer mortality (cycling 0.60, 0.40 to 0.90, P=0.01; mixed mode cycling 0.68, 0.57 to 0.81, P<0.001). Commuting by cycling and walking were associated with a lower risk of CVD incidence (cycling 0.54, 0.33 to 0.88, P=0.01; walking 0.73, 0.54 to 0.99, P=0.04) and CVD mortality (cycling 0.48, 0.25 to 0.92, P=0.03; walking 0.64, 0.45 to 0.91, P=0.01). No statistically significant associations were observed for walking commuting and all cause mortality or cancer outcomes. Mixed mode commuting including walking was not noticeably associated with any of the measured outcomes. Conclusions  Cycle commuting was associated with a lower risk of CVD, cancer, and all cause mortality. Walking commuting was associated with a lower risk of CVD independent of major measured confounding factors. Initiatives to encourage and support active commuting could reduce risk of death and the burden of important chronic conditions.

The BMJ

The book Miracle Pill by British author Peter Walker goes into more depth.

Overall risk of early death among cycle commutersβ€”and yes, this takes into account crashes etcβ€”is 40% lower.
The authors discuss the results here:

https://theconversation.com/cycling-to-work-major-new-study-suggests-health-benefits-are-staggering-76292

Cycling to work: major new study suggests health benefits are staggering

Pedal to the office and your risk of an early death drop by over 40%.

The Conversation
Here's Peter Walker interviewed about his book: https://www.treehugger.com/in-praise-of-stairs-5101268
In Praise of Stairs

According to Peter Walker, they are a "magic pill" that will extend your life.

Treehugger